

Ref. No.: LASA/SE/23-24/31  
Friday, November 10, 2023

<b>To,</b> <b>Corporate Services Department</b> <b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001.</b> <b>BSE CODE –540702</b>	<b>To,</b> <b>Corporate Services Department</b> <b>National Stock Exchange of India Limited</b> <b>“Exchange Plaza”, Plot No. C/1,</b> <b>G Block Bandra-Kurla Complex,</b> <b>Bandra (E), Mumbai – 400 051.</b> <b>NSE CODE: LASA</b>
--	--

Dear Sir/Madam,

Sub. : **Outcome of Board Meeting held today i.e. November 10, 2023**

Pursuant to Regulation 29 and 30 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today which was commenced at 3.00 p.m. and concluded at 5.15 p.m. inter- alia have considered and approved the following:

1. The statement of unaudited Financial Results of the Company for half year ended on September 30, 2023.
2. Limited Review Report from Statutory Auditor for the quarter and half year ended on September 30, 2023.

The above information is also available on the company’s website at [www.lasalabs.com](http://www.lasalabs.com) and on the website of the stock Exchange at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).

**FOR LASA SUPERGENERICS LIMITED**

**MITTI JAIN**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**  
**M. NO.33681**




**Statement of Unaudited Financial Results for Quarter & Six Months ended 30th Sep, 2023**

(Rs in Lakhs)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
<b>1. INCOME</b>						
a Revenue from Operations	2,430.26	3,055.60	3,366.12	5,485.86	6,254.00	12,956.78
b Other Income	8.40	0.39	0.40	8.78	1.27	180.46
<b>Total Income</b>	<b>2,438.66</b>	<b>3,055.98</b>	<b>3,366.53</b>	<b>5,494.64</b>	<b>6,255.26</b>	<b>13,137.24</b>
<b>2. Expenses</b>						
a Cost of Materials consumed	1,965.38	2,220.46	2,069.49	4,185.84	5,714.38	11,012.14
b Cost of Traded Goods	-	-	-	-	-	-
c Change in Inventories of Finished Goods, Work-in-Progress	(314.44)	(189.95)	520.93	(504.39)	(192.23)	(400.71)
d Employee benefits expenses	158.59	169.27	306.52	327.86	625.00	736.81
e Finance costs (Bank Charges)	55.76	37.32	84.03	93.07	84.90	416.05
f Depreciation & amortizations expenses	268.15	265.03	309.49	533.18	616.08	1,341.90
g Other Expenses	516.40	450.78	503.23	967.18	953.66	2,267.90
<b>Total Expenses (a to g)</b>	<b>2,649.83</b>	<b>2,952.91</b>	<b>3,793.68</b>	<b>5,602.74</b>	<b>7,801.79</b>	<b>15,374.09</b>
Exceptional Items	-	-	246.80	-	246.80	1,989.66
<b>3. Profit / (Loss) before tax (1-2)</b>	<b>(211.17)</b>	<b>103.06</b>	<b>(673.95)</b>	<b>(108.10)</b>	<b>(1,793.32)</b>	<b>(4,226.51)</b>
<b>4. Tax expense</b>						
Current Tax	-	-	-	-	-	(368.77)
Deferred Tax	(208.89)	598.03	(17.60)	389.14	71.41	-
Short / Excess income tax provision for earlier years	-	-	4.33	-	4.33	4.33
<b>5. Net Profit / (Loss) after tax (3-4)</b>	<b>(2.28)</b>	<b>(494.97)</b>	<b>(660.67)</b>	<b>(497.23)</b>	<b>(1,869.06)</b>	<b>(3,862.07)</b>
<b>6. Other Comprehensive Income</b>						
Items that will not be reclassified into Profit or Loss						
- Remeasurement of Defined Benefit Plans (Net of tax)	-	-	-	-	-	3.91
<b>7. Total Comprehensive Income for the year (after tax) (5+6)</b>	<b>(2.28)</b>	<b>(494.97)</b>	<b>(660.67)</b>	<b>(497.23)</b>	<b>(1,869.06)</b>	<b>(3,858.16)</b>
<b>8. Paid-up Equity Share Capital (Face Value of Re. 10/- each)</b>	<b>5,010.12</b>	<b>5,010.13</b>	<b>4,067.27</b>	<b>5,010.12</b>	<b>4,067.27</b>	<b>5,952.98</b>
<b>9. Other Equity excluding Revaluation reserve as per Balance Sheet</b>						
<b>10. Earnings per Equity Share (of Rs. 10/- each)</b>						
(a) Basic	(0.00)	(0.99)	(1.62)	(0.99)	(4.60)	(6.49)
(b) Diluted	(0.00)	(0.99)	(1.62)	(0.99)	(4.60)	(6.49)

**Notes :**

- "These interim condensed financial statements are prepared in accordance with Indian Accounting Standard (Ind AS) 34 Interim Financial Reporting, under the historical cost convention on accrual basis except for certain financial instruments which are measured at fair values, the provisions of the Companies Act, 2013 ("the Act") (to the extent notified) and guidelines issued by the Securities and Exchange Board of India (SEBI). Accordingly, these interim condensed financial statements do not include all the information required for a complete set of financial statements. These interim condensed financial statements should be read in conjunction with the financial statements and related notes included in the Company's Annual Report for the year ended March 31, 2023. The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules issued thereafter."
- The Above Financial Results were reviewed by the audit committee of the board on 10th November 2023 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed an unmodified opinion. The auditors report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.
- The Company has paid advances Rs 470 Lakhs to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021 on behalf of Omkar Speciality Chemicals Ltd against which material was supposed to be supplied by OSCL, in the meantime OSCL admitted into CIRP. Company have filed claim with Resolution Professional status of which is still under inspection. The said advance is forming part of Note 12 - Other Current Assets- Advance paid to Suppliers
- Finance Cost for QE Sep'23, includes Rs 55,49,129/- provision for Interest on alleged ECB Loan (Which is Disputed) as per IND AS
- The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind As 108, disclosure of segment information is not applicable.
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.



For LASA Supergenerics Ltd

**Omkar Herlekar**  
Chairman & Managing Director  
(DIN No. 01581154)

Place Mumbai  
Date 10th November 2023

Factory & Regd. Office: E-4, C-14, M.I.D.C. LADY PARSHURAM INDUSTRIAL AREA, TAL- KHED, DIST- RATNAGIRI 415722.  
CIN: L24239MH2003PLC004202 Email: info@lasalabs.com Website: www.lasalabs.com


**LASA SUPERGENERIC LIMITED**  
**CIN: L24233MH2016PLC274202**  
**Condensed Balance Sheet as at Sep 30, 2023**

Particulars	Note No.	As at 30.09.2023	As at 30.09.2022
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, Plant and Equipment	3	8,685.22	11,190.77
Capital Work in Progress	3	464.47	582.44
Intangible assets	3	2,838.26	407.15
<u>Financial Assets</u>			
Non Current Investments	4	-	-
Deposits	5	60.98	1,492.68
		<b>12,048.93</b>	<b>13,673.04</b>
<b>Current assets</b>			
Inventories	6	1,997.58	1,205.80
<u>Financial Assets</u>			
Trade receivables	7	274.67	304.97
Cash and cash equivalents	8	96.77	303.71
Bank balances other than cash & cash equivalents	9	80.45	20.67
Loans	10	5.00	5.00
Other Financial Assets	11	7.55	-
Other current assets	12	2,083.87	2,552.26
		<b>4,545.90</b>	<b>4,392.40</b>
		<b>16,594.82</b>	<b>18,065.45</b>
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
Equity Share capital	13	5,010.12	4,067.27
Other Equity	14	6,321.78	8,927.08
		<b>11,331.90</b>	<b>12,994.35</b>
<b>LIABILITIES</b>			
<b>Non-current liabilities</b>			
<u>Financial Liabilities</u>			
Non Current Borrowings		-	-
Provisions	15	64.52	59.43
Deferred Tax Liabilities	16	612.14	709.14
		<b>676.66</b>	<b>768.57</b>
<u>Current liabilities</u>			
<u>Financial Liabilities</u>			
Current Borrowings	17	105.50	-
Trade payables:	18		
Total outstanding dues of micro enterprises and small enterprises		120.35	208.06
Total outstanding dues of creditors other than micro enterprises and small enterprises		904.85	897.72
Other financial liabilities	19	2,199.26	2,159.39
Other current liabilities	20	144.58	142.29
Provisions	21	1,111.72	895.07
Current tax liabilities (net)		-	-
		<b>4,586.26</b>	<b>4,302.53</b>
		<b>16,594.82</b>	<b>18,065.45</b>

For Gupta Rustagi & Co.  
Chartered Accountants  
Firm Registration No.: 128701W



SD/-  
CA Niraj Gupta  
(Partner)  
M.No.: 100808

Place : Mumbai  
Date : 10th November 2023



For Lasa Supergenerics Limited

*[Signature]*  
OmRaj Herlekar  
(Chairman & Managing Director)  
DIN:01587154

LASA SUPERGENERICS LIMITED			
CIN: L24233MH2016PLC274202			
Statement of Condensed Cash flows for the period ended September 30, 2023			
(Rs. in Lakhs)			
Particulars	Half year ended 30 Sept 2023	Half year ended 30 Sept 2022	Year ended 31 March 2023
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>			
Net (loss) / profit before tax	(108.10)	(1,546.53)	(2,236.85)
<b>Adjustments for</b>			
Depreciation and Amortisation Expense	533.18	616.08	1,341.90
Finance Costs	93.07	84.90	416.06
Interest income	1.33	0.46	(180.46)
Remeasurement of employee defined benefit obligation	-	-	5.05
Exceptional Items	-	(246.80)	(1,989.66)
Profit on Sale of Investments	(7.43)	-	-
<b>Operating profit before working capital changes</b>	<b>512.06</b>	<b>(1,091.88)</b>	<b>(2,643.98)</b>
<b>Working capital adjustments :-</b>			
(Increase) / Decrease in Trade and Other Receivables	(26.88)	1,544.20	1,607.98
(Increase) / Decrease in Inventories	(607.28)	(56.03)	(240.53)
(Increase) / Decrease in Loans	-	(1,431.36)	(1.18)
(Increase) / Decrease in Other Current Assets	(43.92)	(82.67)	(142.29)
Increase / (Decrease) in Trade and Other Payables	82.47	(476.64)	(748.29)
Increase / (Decrease) in Provisions	101.40	299.03	410.27
Increase / (Decrease) in Other Financial Liabilities	22.27	142.30	159.90
Increase / (Decrease) in Other Current Liabilities	5.77	(22.43)	(127.58)
<b>Cash generated from / (used in) operations</b>	<b>45.88</b>	<b>(1,175.48)</b>	<b>(1,725.71)</b>
Direct taxes paid (Net of Refunds)	-	(4.33)	(4.33)
<b>Net cash (used in) / from generated from operating activities</b>	<b>45.88</b>	<b>(1,179.81)</b>	<b>(1,730.04)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>			
Purchase of property, plant & equipment and intangible assets (including capital work-in-progress and capital advances)	(160.86)	(129.63)	483.29
Net (investments in)/ proceeds from bank deposits (having original maturity of more than three months)	78.62	594.43	455.73
Net proceeds from Non Current Investments	31.16	-	-
Profit on Sale of Non Current Investments	7.43	-	-
Increase / (Decrease) In Deposits	3.46	-	-
Interest received	(1.33)	(0.46)	180.47
<b>Net cash (used in) / generated from investing activities</b>	<b>(41.52)</b>	<b>464.34</b>	<b>1,119.49</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>			
Proceeds from Issue of Share Capital ( Considered as deemed inflow)	-	-	(416.06)
Proceeds from Capital Reserve	-	-	(416.06)
Interest paid	(93.07)	(84.90)	-
Proceeds from long-term borrowings (net)	-	-	(1,026.61)
Proceeds from short-term borrowings (net)	105.50	-	1,106.56
Redemption of investment	-	-	79.95
<b>Net cash (used in) / from financing activities</b>	<b>12.43</b>	<b>(84.90)</b>	<b>-</b>
<b>Net decrease in cash and cash equivalents (A+B+C)</b>	<b>16.79</b>	<b>(800.38)</b>	<b>74.62</b>
Cash and cash equivalents at the beginning of the year	79.95	1,104.08	5.33
<b>Cash and cash equivalents at the end of the year</b>	<b>96.74</b>	<b>303.71</b>	<b>79.95</b>
<b>Components of cash and cash equivalents considered only for the purpose of cash flow statement</b>			
In bank current accounts in Indian rupees	76.74	276.63	74.62
Cash on hand	20.01	27.07	5.33
	<b>96.74</b>	<b>303.71</b>	<b>79.95</b>
For Gupta Rustagi & Co. Chartered Accountants Firm Registration No.: 128701W			
SD/- CA Niraj Gupta (Partner) M.No.: 100808	For Lasa Supergenics Limited  Omkar Verlekar (Chairman & Managing Director) DIN:01587154		
Place : Mumbai Date : 10th November 2023			

**Independent Auditor’s Limited Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To

**The Board of Directors of**

**Lasa Supergenerics Ltd**

1. We have reviewed the accompanying statement of unaudited standalone financial results (The “Statement”) of **Lasa Supergenerics Ltd** (‘the Company’) for the quarter ended September 30 ,2023 and year to date from April 01, 2023 to September 30, 2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”)
2. The statement which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of Material misstatement. A review is limited primarily to inquires of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. As mentioned in Note 3 of the Statement wherein the Company has mentioned has paid advances Rs.470 Lakhs to Arch Herbals Pvt Ltd in the Financial Year 2020 and 2021 on behalf of Omkar Speciality Chemicals Ltd (OSCL) against which material was supposed to be supplied by OSCL, in the meantime OSCL was admitted into CIRP on 20.12.2022, Company have filed claim with Resolution Professional status of which is still under inspection.. The said advance is forming part of Other Current Assets- Advance paid to Suppliers.. As mentioned in Note 3 of the accompanying statement of unaudited standalone financial results the Company has continued to carry this advance at book value. The impact of the same on the standalone financial statement of the Company is unascertainable at this stage.

## 5. Emphasis of Matter

The company does not have insurance cover for any of its assets. We are informed that company had disputed the insurance settlement amount offered by the insurance company against the claim filed by the company (flood insurance claim pertaining to 2019-20). The company should take immediate steps to resolve the issue and obtain necessary insurance cover to avoid any contingencies for which no provision has been made.

6. Based on our review conducted as above, *except for the possible effects of our observations in paragraph 4 above*, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable accounting standard and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation ,2015 including the manner in which it is to be disclosed , or that it contains any material misstatement.

For **Gupta Rustagi & CO.**

Chartered Accountants

ICAI FRN : 128701W

**Niraj  
Subhashch  
and Gupta**

Digitally signed by  
Niraj Subhashchand  
Gupta  
Date: 2023.11.10  
14:51:01 +05'30'

Niraj Gupta

Partner

M.N.no. 100808

UDIN: 23100808BGVNXI7156